Biohit Oyj

Business and Financial Review • Jun 4, 2020

Disclosure 384538

Biohit Oyj - Inside information

Biohit Group’s Net Sales outlook for 2020 changed

Biohit Oyj Stock Exchange Release The coronavirus (2019-nCoV) has impacted negatively on the demand of the company’s products globally and due to that Biohit Group’s Net Sales outlook for 2020 has changed. Biohit’s new outlook for 2020: Biohit expects the 2020 Net Sales to decrease in comparison with 2019 (previous year EUR 10.1 million). Biohit’s previous outlook for 2020: Biohit expects the 2020 Net Sales to increase in comparison with 2019 (previous year EUR 10.1 million). During the first half of the year 2020 Biohit Net Sales will decrease significantly comparing H1/2019. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=F7USWVHKzHva X-wfSDZQcANme4hiXnyDOMsYd7_hh0-v5DJ8cXf2bZjeB -DIAzDZFpopELnpgMmEnA_kpyYmLGTqvkGETAk2QfpwclEc6SE=) Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=F7USWVHKzHva X-wfSDZQcANme4hiXnyDOMsYd7_hh0-HphCZT -UWUifHMeiFjvXkBDZQ62S4EwZW_vCTZLKUtXA4wJQzLvKWLu5SyZMTKVM=)